Source: Annual Congress 2007 - Pulmonary circulation
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Zagolin, P. Uriarte, E. Wainstein, C. Parra (Santiago, Chile). Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension. Eur Respir J 2007; 30: Suppl. 51, 2099

Member's Comments

No comment yet.

Related content which might interest you: Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Hemodynamic testing of acute vasoreagibility to sildenafil in patients with severe pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004 Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Sitaxsentan for pulmonary arterial hypertension (PAH) patients with clinical deterioration or significantly abnormal liver function test on bosentan Source: Eur Respir J 2005; 26: Suppl. 49, 563s Year: 2005 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Clinical and hemodynamic long term efficacy of sildenafil in primary pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Long-term effects of bosentan on the heart and pulmonary hemodynamics in pulmonary arterial hypertension, a comparison study with epoprostenol Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 205s Year: 2005 Clinical characteristics, haemodynamics, and survival in patients with combined pulmonary fibrosis and emphysema and associated pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular medicine Year: 2008 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2015; 46: 405-413 Year: 2015